Professor Isabelle Koné-Paut has been the head of the pediatric rheumatology department at the Kremlin Bicêtre hospital, university of Paris Sud-Saclay. Her department is a EULAR Center of Excellence (2015/2020 and 2020/2025). Prof Koné-Paut coordinates the national reference center for rare autoinflammatory diseases and inflammatory amyloidosis (including seven sites) (CEREMAIA (http://www.ceremaia.fr) since 2007. She has created the first pediatric inflammatory rheumatism care network (RESRIP: http://www.resrip.fr) in 2012.

Professor Koné-Paut started pediatric rheumatology in 1988 and was the second doctor to practice this specialty, at the pioneering time, in France. Her clinical research activities began with a focus on pediatric Behçet's disease and familial Mediterranean fever in a clinicogenetic duo with Isabelle Touitou. After this time in Marseille, she broadened her research in Paris to other autoinflammatory diseases and Kawasaki disease. She has personally developed and collaborated on numerous projects exploring interleukin 1 as a therapeutic target and patient-reported outcome measures. She has collaborated in various international organizations and projects: ERN RITA, PRINTO, EUROFEVER, JIR cohort, and IMMUNAID among others. Professor Koné-Paut has participated in several pedagogic works and, she is the author of numerous international publications, the most significant of which concern Pediatric Behçet's disease, familial Mediterranean fever, CAPS syndromes, and Kawasaki disease. She has held various positions in academic societies: President of SOFREMIP (French society of pediatric rheumatology), board member of the French Society of Pediatrics, Pediatric rheumatology European society, International society for autoinflammatory diseases, and the International Society of Behçet (ISBD). She has set up a European group for the study of Kawasaki disease: EuroKiDs, and organized the first meeting in Paris in 2021. Finally, she has received awards: APPINOV trophy (APHP) and Groupama foundation for the AIDAI score, KOURIR price (EULAR) for the KAWAKINRA Trial, and MERDOCHAI PRAS AWARD of the ISSAID SOCIETY for clinical science in SAIDs.